Peter Chambré
Chairman chez IMMATICS N.V.
Fortune : 4 M $ au 31/03/2024
Profil
Peter Alan Chambré is currently the Chairman at Cancer Research Technology Ltd., 7TM A, Immatics US, Inc., Immatics NV, 7tm.
Holding ApS, Cancer Research UK, and Our Future Health Uk.
He previously served as the Chief Executive Officer at MedImmune Ltd., Consort Medical Ltd., and Cambridge Antibody Technology Group Ltd.
He was also the Chairman at ApaTech Ltd., Immatics Biotechnologies GmbH, Xellia Pharmaceuticals AS, and OneMed AB.
Additionally, he held positions as an Independent Non-Executive Director at Touchstone Innovations Ltd., Spectris Plc, and BTG Ltd.
He has also worked as an Advisor at 3i Group Plc and as a Principal at Unilever Plc and Bain & Co., Inc. Furthermore, he served as the Chief Operating Officer at Celera Group.
Mr. Chambré has a degree from The University of Reading.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V.
0,36% | 31/01/2024 | 373 274 ( 0,36% ) | 4 M $ | 31/03/2024 |
Postes actifs de Peter Chambré
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Chairman | 01/10/2012 |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Chairman | 01/10/2011 |
Our Future Health Uk
 Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam. | Director/Board Member | - |
| 7tm Holding ApS | Chairman | - |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Chairman | 01/11/2012 |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Chairman | - |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Director/Board Member | 01/01/2016 |
Anciens postes connus de Peter Chambré
| Sociétés | Poste | Fin |
|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chairman | 01/01/2020 |
OneMed AB
 OneMed AB Medical DistributorsDistribution Services OneMed AB distributes consumable medical products, devices, and technology in the healthcare industry. It also supplements its product range with services within purchasing, logistics, administration, information technology, support, education, product range planning, ordering procedures, as well as providing know-how on healthcare consequences and product management. Its product portfolio consists of products evercare, SELEFA, and BATIST. The firm offers Gloves; Surgical drapes, sets and gowns; Minor procedure sets; Protective apparel; Surgical masks and caps; Wound care and bandages; Paper and plastic protection; and Consumables. The company was founded in 2006 and is headquartered in Danderyd, Sweden. | Chairman | 01/01/2019 |
| ░░░░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter Chambré
| The University of Reading | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| 3I GROUP PLC | Finance |
| UNILEVER PLC | Consumer Non-Durables |
| SPECTRIS PLC | Producer Manufacturing |
| IMMATICS N.V. | Health Technology |
| Entreprise privées | 18 |
|---|---|
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Consort Medical Ltd.
 Consort Medical Ltd. Pharmaceuticals: MajorHealth Technology Consort Medical Ltd. is a holding company, which engages in pharmaceutical industry related activities. It focuses on the design, development, manufacture, and sale of medical drug and delivery devices. The company was founded on March 22, 1946 and is headquartered in Kings Lynn, the United Kingdom. | Health Technology |
Touchstone Innovations Ltd.
 Touchstone Innovations Ltd. Investment ManagersFinance Touchstone Innovations Ltd. engages in the provision of technology and commercialization services. The company was founded by Susan Jane Searle in 1986 and is headquartered in London, the United Kingdom. | Finance |
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services UDG Healthcare Plc engages in the supply and distribution of pharmaceutical and medical products. It operates through the following segments: Ashfield, Sharp, and Aquilant. The Ashfield segment provides commercialization services for the pharmaceutical and healthcare industry. The Sharp segment offers contract packaging and clinical trial packaging services. The Aquilant segment involves. outsourced sales, marketing, distribution, and engineering services to the medical and scientific sectors. The company was founded in 1948 and is headquartered in Dublin, Ireland. | Commercial Services |
Bain & Co., Inc.
 Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Commercial Services |
Celera Group
 Celera Group Pharmaceuticals: MajorHealth Technology Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD | Health Technology |
ApaTech Ltd.
 ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Cancer Research Technology Ltd.
Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Health Technology |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Health Technology |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Commercial Services |
Xellia Pharmaceuticals AS
 Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Health Technology |
OneMed AB
OneMed AB Medical DistributorsDistribution Services OneMed AB distributes consumable medical products, devices, and technology in the healthcare industry. It also supplements its product range with services within purchasing, logistics, administration, information technology, support, education, product range planning, ordering procedures, as well as providing know-how on healthcare consequences and product management. Its product portfolio consists of products evercare, SELEFA, and BATIST. The firm offers Gloves; Surgical drapes, sets and gowns; Minor procedure sets; Protective apparel; Surgical masks and caps; Wound care and bandages; Paper and plastic protection; and Consumables. The company was founded in 2006 and is headquartered in Danderyd, Sweden. | Distribution Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
Cambridge Antibody Technology Group Ltd.
 Cambridge Antibody Technology Group Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a holding private company that oversees its subsidiaries' research, development, and exploitation of molecular engineering products. The company is based in Cambridge, UK and was founded in 1996. | Commercial Services |
| 7tm Holding ApS | |
Our Future Health Uk
Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam. | Commercial Services |
